Protech Home Medical Announces Closing of $3.4 Million Bought Deal Offering & $1.1 Million Insider Non-Brokered Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CINCINNATI, Ohio, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (“PHM” or the “Company”) (TSXV: PHM), is pleased to announce that it has completed its previously announced bought deal private placement of common shares (the “Offered Shares”) of the Company, at a price of $0.12 per Offered Share (the “Issue Price”) for gross proceeds to the Company of $3,389,760 (the “Offering”). A total of 28,248,000 Offered Shares were sold pursuant to the Offering, including 3,248,000 Offered Shares issued as a result of the partial exercise of the Underwriter’s over-allotment option. The Offering was conducted by Beacon Securities Limited (the “Underwriter”).
PHM is also pleased to announce that it has completed its previously announced non-brokered private placement of common shares of the Company at the Issue Price for gross proceeds to the Company of $1,100,000. A total of 9,166,666 common shares of the Company were sold pursuant to the non-brokered private placement to Gregory Crawford (CEO), Hardik Mehta (CFO), and Eugene Ewing (Independent Director).
“This financing is a testimony of the confidence that PHM has gained in the short amount of time since the new management team has been in place. I strongly believe that PHM will reach new heights over the next 12-18 months as we execute our corporate strategy on the back bone of our robust balance sheet”, said Greg Crawford, Chairman and CEO of PHM.
All securities issued in connection with the above noted financings are subject to a hold period which will expire on March 3, 2019, the date that is four months and one day from the closing of the financings.
The Company paid to the Underwriter a cash commission equal to 6.5% of the gross proceeds raised under the Offering. The Company also issued to the Underwriter compensation options (the “Compensation Options”) equal to 6.5% of the Offered Shares issued pursuant to the Offering. Each Compensation Option is exercisable into one common share of the Company at the Issue Price for a period of 24 months from the closing of the Offering.
The net proceeds from the financings will be used for working capital and general corporate purposes.
The subscriptions from the officers and directors in the non-brokered private placement is a "related party transaction" as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation requirements of MI 61-101 as none of the securities of the Company are listed on a prescribed stock exchange. The transaction is exempt from the minority shareholder approval requirements of MI 61-101 as, at the time the transaction was agreed to, neither the fair market value of, nor the fair market value of the consideration for, the transaction, insofar as it involves interested parties, exceeded 25% of the Company's market capitalization.
The offered securities have not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
ABOUT PROTECH HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services for patients in the United States healthcare market. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.
For further information please visit our website at www.protechhomemedical.com, or contact:
Chief Financial Officer
Protech Home Medical Corp.
Neither the TSXV nor its Regulation Service Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. All statements other than statements of historical fact, included herein, including without limitation, statements regarding the use of proceeds from the financings, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects”, "anticipates”, "believes”, "intends”, "estimates”, "potential”, "possible”, and similar expressions, or statements that events, conditions, or results "will”, "may”, "could”, or "should” occur or be achieved. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: credit; market (including equity, commodity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; and the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Upcoming Life Sciences Events
- December 2018
- London: The Pharma Business Development Course - An Overview Course
- London: Genesis 2018
- January 2019
- San Francisco: Biotech Showcase